B‐cell maturation antigen chimeric antigen receptor‐T therapy alleviated heart failure in patients with multiple myeloma

Abstract

Abstract Patients with multiple myeloma (MM) are likely to achieve poor therapeutic response when organs are involved. We produced anti‐B‐cell maturation antigen (BCMA) chimeric antigen receptor (CAR)‐T cells, which are in a trial for patients with relapsed/refractory MM. One enrolled patient developed severe heart failure, highly suspected as light chain cardiac amyloidosis. He exhibited increased N‐terminal pro‐brain natriuretic peptide with a peak of 32 299 ng/mL and heart failure with an ejection fraction of 30%. Anti‐BCMA CAR‐T cells were administered following lymphodepletion. The patient achieved cardiac response within 1 week with a decrease in N‐terminal pro‐brain natriuretic peptide by 80%, an increase in ejection fraction from 30% to 56%, and a haematological response with negative minimal residual disease at 1 month and a complete response at 1 year. To date, this patient has maintained good health without heart failure or haematological relapse. Herein, we show the efficacy of anti‐BCMA CAR‐T cells in patients with MM and severe heart failure.

Keywords

• Anti‐B‐cell maturation antigen
• Chimeric antigen receptor‐modified T cells
• Light chain cardiac amyloidosis
• Multiple myeloma